News

latest corporate presentation

Latest Summary Corporate Presentation

June 2024

View Presentation
26 Jun 2024 PR Newswire Positive Xanamem® biomarker trial published in the Journal of Alzheimer’s Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau
03 Jun 2024 Actinogen Video Recording: ACW Australian Dementia Research Forum poster presentation
24 May 2024 Actinogen Webcast Video Recording: Actinogen Clinical Trials Science Forum 2024 – Pipeline in a Pill
06 May 2024 Actinogen Video interview: [2:49 mins] Market Link interview with ACW CEO, Steven Gourlay
03 May 2024 Corporate Presentations Video Presentation: Actinogen May 2024 $8.9m capital raising webinar
22 Apr 2024 PR Newswire Enrolment completed in Actinogen’s XanaCIDD phase 2a cognition & depression trial
15 Apr 2024 PR Newswire First patient treated in Actinogen’s XanaMIA phase 2b Alzheimer’s disease trial
24 Jan 2024 PR Newswire Positive Xanamem® human PET study published in the Journal of Alzheimer’s Disease demonstrating robust CNS target enzyme occupancy
08 Jan 2024 Corporate Presentations Company Presentation: ACW CEO & CMO present at Sachs Neuroscience Innovation Forum & JPM week meetings
07 Jan 2024 Corporate Presentations Video Presentation: ACW CMO presents at Sachs Neuroscience Innovation Forum
28 Nov 2023 PR Newswire Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
15 Nov 2023 Corporate Presentations Company Presentation: ACW CEO presents at Bell Potter Healthcare Conference 2023
25 Oct 2023 Corporate Presentations Company Presentation: ACW CMO presents academic poster at CTAD 2023 conference
18 Oct 2023 Corporate Presentations Company Presentation: ACW CEO presentation for meetings at BIO Investor Forum USA
13 Oct 2023 PR Newswire Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer’s Disease (CTAD) Conference, Boston
06 Oct 2023 Actinogen Company Presentation: ACW CEO presents to Dementia Trials Australia conference
29 Sep 2023 Actinogen Company Presentation: ACW Clinical Scientist presents to the Asian Society Against Dementia congress
26 Sep 2023 PR Newswire Actinogen optimizes XanaMIA Phase 2b Alzheimer’s disease trial design and provides general business update
14 Sep 2023 Actinogen Video interview: [14.46 mins] Xanamem program update
31 Aug 2023 Media Webcast video recording: Actinogen neuroscience webinar
07 Jun 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
05 Jun 2023 Media Insight: Beyond the amyloid hypothesis – how small molecules are giving hope to Alzheimer’s research
31 May 2023 PR Newswire Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer’s Disease Phase 2 trials at the BIO International Convention
24 May 2023 Actinogen Webcast video recording: Actinogen Clinical Trials Science Forum 2023
30 Mar 2023 PR Newswire Actinogen presents positive Phase 2a Xanamem data at AD/PD™ Alzheimer’s and Parkinson’s diseases conference
30 Mar 2023 Actinogen Oral presentation: CMO presentation at Alzheimer’s and Parkinson’s Disease Conference (AD/PD™) in Gothenburg, Sweden
01 Mar 2023 Biotech Daily Actinogen Appoints Nicki Vasquez Non-Executive Director
24 Feb 2023 Actinogen Company presentation: Spark Plus Biotech Conference in Singapore
01 Feb 2023 Biotech Daily Actinogen Appoints Dr Dana Hilt CMO
09 Jan 2023 Actinogen Company presentation: Sachs Neuroscience Innovation Forum and other meetings during the JP Morgan Healthcare Conference week
22 Dec 2022 PR Newswire FDA agrees to Actinogen six-month Phase 2b Alzheimer’s Disease trial
14 Dec 2022 PR Newswire Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
03 Dec 2022 Actinogen Poster presentation: CTAD conference 2022
25 Nov 2022 Biotech Daily Dr Boreham’s Crucible: Actinogen Medical
16 Nov 2022 Actinogen Webcast video recording: AGM 16 Nov 2022 ACW Chair’s Address and CEO presentation
16 Nov 2022 Actinogen Company presentation: AGM 16 Nov 2022 ACW Chair’s Address and CEO presentation
09 Nov 2022 Bell Potter Webcast video recording: CEO presentation to Bell Potter Healthcare Conference 2022
09 Nov 2022 Actinogen Company presentation: CEO presentation to Bell Potter Healthcare Conference 2022
03 Nov 2022 SparkPlus Webinar video recording: CEO presentation at Spark Plus Healthcare Day
03 Nov 2022 Actinogen Company presentation: CEO presentation to Spark Plus Healthcare Day
24 Oct 2022 ShareCafe Webinar video recording: CEO presentation at ShareCafe “Hidden Gems”
21 Oct 2022 Actinogen Company presentation: CEO presentation at ShareCafe “Hidden Gems”
19 Oct 2022 Stockhead Alzheimer’s drug no longer a moonshot as race heats up, ASX-listed Actinogen in the running
11 Oct 2022 EIN Presswire Actinogen Medical (ACW) announces large Xanamem® therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
10 Oct 2022 Actinogen Webcast video recording: Alzheimer’s Disease biomarker study clinical results – Large clinical benefit on FDA-approved measurement of cognition and function in patients with Alzheimer’s Disease
10 Oct 2022 Biotech Daily Actinogen Xanamem Alzheimer’s Biomarker Effect
10 Oct 2022 Actinogen Company presentation: Alzheimer’s Disease biomarker study clinical results – Large clinical benefit on FDA-approved measurement of cognition and function in patients with Alzheimer’s Disease
10 Oct 2022 PR Newswire Actinogen Medical Limited (ACW) announces large Xanamem therapeutic effect in early-stage Alzheimer’s Disease (AD) patients
13 Sep 2022 Actinogen Company presentation: Xanamem® Clinical Program Update – Alzheimer’s Disease (AD) biomarkers – context and history
11 Aug 2022 Actinogen Company presentation: CEO presentation for non-deal roadshow investor meetings

Back
to top